Six readers
| reader | found | score |
|---|---|---|
| genetics Open Targets | no genetic evidence; overall 0.09 from other evidence | 0.00 |
| cell type Human Protein Atlas | expressed broadly, no clear home in brain cells | 0.40 |
| chemistry Open Targets | compounds already reach it: vatelizumab | 0.81 |
| trials ClinicalTrials.gov | no Parkinson's trials on record: an open field | 1.00 |
| literature PubMed | no papers tie it to Parkinson's yet | 1.00 |
| pathways Reactome | 8 pathways; mostly other | 0.30 |
No case: the score is under the bar. Receipt 3048
Sealed predictions
- ITGA2 in dopamine neurons, braak+0.13 (p 0.739) → -0.14 (p 0.723)receipt 3055
Swarm cases
receipt 3055: ITGA2 in dopamine neurons, braak
- power
- full sample -0.05 (p 0.840, n 18), 95% CI -0.51 to +0.43. the interval is wide: not enough donors to tell.
- confounder
- adjusted for sex: -0.06 (p 0.820, n 18). does not hold up.
- composition
- dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.22 (p 0.389, n 18). could be the mix.
- skeptic
- leave-one-out range -0.18 to +0.06, sign flips 4; without severely affected donors -0.05 (p 0.840, n 18). fragile.
- cell type
- no other cell group does better.
- axis
- no measure beats "tracks Braak Lewy-body stage" for ITGA2 in dopamine neurons.
case closed: nothing better to follow up.
Receipts
loading the receipts